Edesa Biotech Covid-19 Drug Candidate Gets Positive Review from Independent Data Group
June 18 2021 - 9:07AM
Dow Jones News
By Adriano Marchese
Edesa Biotech Inc. said Friday that an independent committee has
recommended that the company's Covid-19 drug candidate study
continue as planned.
The clinical-stage biopharmaceutical company said the Data and
Safety Monitoring Board, which monitors patient safety and
treatment efficacy data during clinical trials, recommended that
enrollment in the trial continue.
The recommendation follows an interim review of the first
patient cohort participating in Edesa's Phase 2/3 clinical study
for the EB05 drug candidate, a single-dose treatment for more
serious cases of Covid-19.
Edesa said it has filed a trial amendment with the Food and Drug
Administration to streamline the U.S. protocol and align it with
other jurisdictions.
"These planned changes could significantly reduce the number of
additional patients enrolled in the study and could put us in the
position to demonstrate results sooner," Vice President of Research
and Development Blair Gordon said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
June 18, 2021 08:54 ET (12:54 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.